Between February 1, 2013 and the date of the Meeting, no February Warrants may be exercised. If the requisite shareholder approval is not received, the February Warrants will terminate as at the date of the Meeting and the June Warrants will terminate on June 1, 2013.

A bout GeneNews

GeneNews is a molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry™, is the world's first blood test to pre-screen and assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry™, go to or

Forward-Looking Statements

This press release contains forward-looking statements, which reflect GeneNews' current expectations regarding the future extension of the warrants of GeneNews. The forward-looking statements involve risks and uncertainties, including the result of the disinterested shareholder vote to extend the Warrants. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings, annual information form and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Subject to applicable law, the Company disclaims any obligation to update these forward-looking statements.
CONTACT: Company Contact:         Gailina Liew         President & COO         Office: (905) 739-2036         Mobile: (416) 844-0649                  Investor & Media Contact:         Stephen Kilmer         Kilmer Lucas Inc.         Office: (212) 618-6347         Mobile: (905) 906-6908

If you liked this article you might like

News Out of Europe: Intesa Confirms Potential Bid for Generali

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

5 Stocks Under $10 Set to Soar

7 Stocks Under $10 to Trade for Big Breakouts

5 Stocks Under $10 Set to Soar